Terns Pharmaceuticals Strengthens Leadership
Terns Pharmaceuticals, Inc., a notable player in the biopharmaceutical sector dedicated to developing therapies for serious conditions such as oncology and obesity, has made a significant leadership change with the appointment of Andrew Gengos as the new Chief Financial Officer.
Background on Andrew Gengos
Andrew Gengos brings a wealth of experience, having accumulated over 25 years of expertise in finance and corporate strategy specifically within life sciences and biotechnology. His previous role was as CFO at Athira Pharma, where he oversaw financial strategies and guided the company's financial health.
A Track Record of Success
Before his tenure at Athira, Mr. Gengos held the position of Chief Business Officer at Cyteir Therapeutics. There, he demonstrated his leadership by successfully guiding the finance team through the complexities of taking the company public. His diverse experience includes significant leadership roles at ImmunoCellular Therapeutics and Neuraltus Pharmaceuticals, where he helped steer companies through multiple therapeutic areas, particularly in oncology and neurodegenerative diseases.
What This Means for Terns Pharmaceuticals
In his new role, Mr. Gengos is expected to leverage his vast industry knowledge to bolster Terns' financial strategy and support ongoing product development. The company's CEO, Amy Burroughs, expressed confidence in Gengos’ ability to drive growth and contribute to Terns’ mission of improving lives through innovative therapies.
Advancing Critical Programs
Mr. Gengos has already shown eagerness about his new responsibilities, saying, "I am pleased to be joining Terns as we advance our lead oncology and obesity programs towards compelling clinical readouts." His commitment to working alongside the current leadership team showcases a united front aimed at achieving substantial milestones in drug development.
About Terns Pharmaceuticals
Terns Pharmaceuticals is not just focusing on one or two products; they're building a robust pipeline. The company’s development programs include a diverse range of therapies, such as an allosteric BCR-ABL inhibitor and multiple receptor modulators designed to tackle obesity and enhance metabolic health.
Commitment to Innovation
The company has dedicated itself to addressing unmet needs in clinical therapy for serious diseases. Not only are they actively engaged in clinical trials, but they are also concentrating on research that enhances patient outcomes and fosters a better quality of life through new medications.
Company Contacts
For investors looking for more information about Terns Pharmaceuticals, the company directs inquiries to Justin Ng at investors@ternspharma.com.
Media inquiries can be directed to Jenna Urban at CG Life via media@ternspharma.com.
Frequently Asked Questions
1. Who has been appointed as the CFO of Terns Pharmaceuticals?
Andrew Gengos has been announced as the new Chief Financial Officer of Terns Pharmaceuticals.
2. What is Andrew Gengos' experience?
Andrew has over 25 years of experience in finance, previously serving as CFO at Athira Pharma and in leadership roles at several biotech companies.
3. What are Terns Pharmaceuticals focusing on?
The company is developing a range of therapies for oncology and obesity, with a commitment to innovative approaches to treatment.
4. How can investors contact Terns Pharmaceuticals?
Investors can reach out via email at investors@ternspharma.com.
5. What is the mission of Terns Pharmaceuticals?
The mission is to transform patients’ lives by developing new medicines that significantly impact health outcomes.
